Amneal Pharmaceuticals, Inc..
American publicly traded generics and specialty pharmaceutical company
- Reports this week
- 0
- Active events
- 0
- Connections
- 24
What's happening
One to three months ago
-
Amneal Pharmaceuticals highlighted positive study results from Kashiv BioSciences and is currently seeking FDA approval for a biosimilar product.Some support2 reports1 development inside
-
Director John Kiely sold company shares of Amneal Pharmaceuticals, Inc. in a transaction disclosed via SEC document.Some support1 report
Gone quiet
No new reports in 90+ days-
The FDA approved additional iohexol injection strengths, with Amneal aiming to meet U.S. market demand.Some support1 report
-
Truist Financial increased its target price for Amneal Pharmaceuticals, Inc.Some support1 report
-
Amneal Pharmaceuticals received a Buy rating from Truist Financial on August 1, 2025, noting that the company benefits from Trump-era tariffs and AI trends.Some support1 report
-
Goldman Sachs initiated coverage on Amneal Pharmaceuticals, noting its headquarters in Bridgewater and Gautam Patel as director.Speculative1 report
-
Chirag was appointed as a Co-Chief Executive Officer of Amneal Pharmaceuticals, Inc.Some support1 report
-
Knight entered into an agreement on August 5, 2025, regarding CREXONT rights with Amneal Pharmaceuticals, Inc.Some support2 reports
-
The FDA approved the Brekiya® autoinjector from Amneal Pharmaceuticals on August 5, 2025.Some support1 report
No events began in the chosen period. Widen it, or reset.
Around Amneal Pharmaceuticals, Inc. this week
News at the entities that move Amneal Pharmaceuticals, Inc. most-
FDA StructuralClene Inc. submitted an NDA to the FDA seeking accelerated approval while trading on the Nasdaq exchange.Moves Amneal Pharmaceuticals, Inc.
-
SEC StructuralMSCI index rules may affect Bitcoin companies, while warnings caused stock market crashes in Turkey and Indonesia.Moves Amneal Pharmaceuticals, Inc.
-
Truist Financial Mentioned togetherTruist Financial analysts dropped the target price for Deckers Outdoor on July 24, 2026.Moves Amneal Pharmaceuticals, Inc.
-
Knight TransactionalKnight invested $1.5B into Pennsylvania and operates projects in Cambria County.Moves Amneal Pharmaceuticals, Inc.
-
Leerink partners Mentioned togetherLeerink Partners is acting as a placement agent for First Tracks Biotherapeutics.Moves Amneal Pharmaceuticals, Inc.
-
Nasdaq Shared contextAirbnb and First Watch Restaurant Group are classified as consumer discretionary companies, and Airbnb is listed on Nasdaq.Moves Amneal Pharmaceuticals, Inc.
Connections
The 7 strongest of 24, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
FDA Structural
FDA formally regulates and approves pharmaceutical products developed by Amneal.
-
SEC Structural
Amneal Pharmaceuticals is subject to formal regulation and disclosure requirements by the SEC.
-
Knight Transactional
Knight and Amneal entered a formal agreement for the exclusive commercialization rights of CREXONT®.
-
Truist Financial Mentioned together
Truist Financial provides investment ratings and target price forecasts for Amneal Pharmaceuticals.
-
John Kiely Structural
John Kiely serves as a Director of Amneal Pharmaceuticals, Inc., and the evidence confirms he sold company shares.
-
Leerink partners Mentioned together
The relationship is based on shared market research coverage and analyst ratings.
-
Nasdaq Shared context
Amneal Pharmaceuticals is listed and traded on the Nasdaq exchange.
History
Events by the month they beganAugust 2026
1 eventJuly 2026
1 eventJune 2026
7 events- Amneal Pharmaceuticals highlighted positive study results from Kashiv BioSciences and is currently seeking FDA approval for a biosimilar product.
- Truist Financial increased its target price for Amneal Pharmaceuticals, Inc.
- Amneal Pharmaceuticals received a Buy rating from Truist Financial on August 1, 2025, noting that the company benefits from Trump-era tariffs and AI trends.
- Goldman Sachs initiated coverage on Amneal Pharmaceuticals, noting its headquarters in Bridgewater and Gautam Patel as director.
- Chirag was appointed as a Co-Chief Executive Officer of Amneal Pharmaceuticals, Inc.
- Knight entered into an agreement on August 5, 2025, regarding CREXONT rights with Amneal Pharmaceuticals, Inc.
- The FDA approved the Brekiya® autoinjector from Amneal Pharmaceuticals on August 5, 2025.